Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
All participants received tirzepatide for 36 weeks, alongside diet and exercise support, before being randomly split into two equal-sized groups, one of which continued the medication for a further 52 weeks, while the other switched to a placebo for this period
Schedule: Subcutaneous injections 3 times weekly (Mon/Wed/Fri) for 816 weeks
Clinical Data Phase 2 clinical studies of cagrilintide monotherapy in adults with obesity reported dose-dependent weight reductions of 6.0% to 10.8% over 26 weeks with a favourable tolerability profile
Klow is intended for in-vitro and non-clinical in-vivo research only
Peptides arrive as a powder
Who shouldn't use tirzepatide
US$ 27.55
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
US$ 27.33
US$ 22.60
US$ 27.62
US$ 21.40
US$ 23.12
US$ 26.38
US$ 28.42
US$ 29.53
